Project Grant R44CA203068

This Project Grant award from the National Cancer Institute (NCI), under CFDA program 93.394 Cancer Detection and Diagnosis Research, provides $1,999,108 to Orbit Genomics, Inc. to develop a high-sensitivity, high-specificity diagnostic test for lung cancer subtyping. The goal is to create a test that can accurately distinguish between different lung cancer subtypes, which is critical for selecting the most effective treatment and reducing mortality. The project will involve obtaining patient...

This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...

This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $244,228 to the University of Texas MD Anderson Cancer Center to develop a comprehensive proteomics-based approach to accurately map patient tumor samples to preclinical lung cancer models. The key products and services to be delivered include: (1) expanding proteomics profiling of lung cancer patient-derived xenograft (PDX) models using the reverse-phase protein...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $1,625,000.00 to Onc.ai, Inc. to develop and validate a radiomics-based multi-modal predictive model for metastatic non-small cell lung cancer patients treated with PD-1 immunotherapy. The key objectives are to: 1) Validate the predictive models in a multi-institutional prospective clinical study, 2) Evaluate the performance characteristics and...

This $374,123 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will establish a "Rapid Multiplexed Protein Interaction (RAPMPI)" method to study drug-sensitive and resistant non-small cell lung cancer (NSCLC) cells with epidermal growth factor receptor (EGFR) gene mutations. The project aims to map the spatial signaling interactors and subcellular localization of key proteins to define combination therapies that can overcome...

The National Cancer Institute (NCI) awarded a $990,771 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Binary Genomics, Inc., a minority-owned for-profit organization located in Madison, CT. The project aims to build clinical data supporting the use of Binary Genomics' circulating tumor DNA (ctDNA) assay technology for monitoring the efficacy of lung cancer immunotherapies. The technology leverages epigenetic features to broadly detect ctDNA without...

This Project Grant award from the National Cancer Institute (NCI), under the federal grant program "Cancer Detection and Diagnosis Research" (CFDA 93.394), provides $2,078,214 to Precision Epigenomics Inc., a University of Arizona spin-out company, to conduct a multi-site clinical validation study for their "Sentinel-MPE" liquid biopsy assay. The aim is to establish the diagnostic value of this test to identify cancer in pleural effusions and validate its use for cancer...

This Project Grant award of $602,315 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) aims to validate a novel mouse model of lung squamous cell carcinoma (SCC) premalignancy and leverage it to screen and test new prevention agents. The key objectives are: Defining the human relevance of the in vivo NTCU/cigarette smoke mouse model of lung SCC premalignancy. Validating an ex vivo precision cut lung slice approach to screening potential prevention agents...

This $321,304 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the advancement of PDX Pharmaceuticals' nanoparticle-based immunotherapy for the treatment of non-small cell lung cancer (NSCLC). The key activities funded under this award are: Protecting the intellectual property (IP) of PDX's nanoparticle delivery platform (PDX-NP) and the lead ARAC-02 immunotherapy, including pursuing international patent protection and...